Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGN NASDAQ:EGRX NYSE:NNVC NASDAQ:PYRGF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/AEGRXEagle Pharmaceuticals$1.50-50.0%$3.15$0.11▼$3.87$19.48M0.836,495 shs30,081 shsNNVCNanoViricides$1.42-0.7%$1.46$0.94▼$1.92$24.58M1.16220,953 shs51,233 shsPYRGFPyroGenesis Canada$0.20+3.0%$0.21$0.14▼$0.68$36.57M0.7817,379 shs83,364 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGNApexigen0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals0.00%+11.11%-6.54%-15.49%+445.45%NNVCNanoViricides+1.06%-0.69%-0.69%+1.42%+0.70%PYRGFPyroGenesis Canada+3.33%+17.43%+1.12%-43.91%-69.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGNApexigen$0.39$0.39$0.33▼$8.28$9.57M3.6967,731 shsN/AEGRXEagle Pharmaceuticals$1.50-50.0%$3.15$0.11▼$3.87$19.48M0.836,495 shs30,081 shsNNVCNanoViricides$1.42-0.7%$1.46$0.94▼$1.92$24.58M1.16220,953 shs51,233 shsPYRGFPyroGenesis Canada$0.20+3.0%$0.21$0.14▼$0.68$36.57M0.7817,379 shs83,364 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGNApexigen0.00%0.00%0.00%0.00%0.00%EGRXEagle Pharmaceuticals0.00%+11.11%-6.54%-15.49%+445.45%NNVCNanoViricides+1.06%-0.69%-0.69%+1.42%+0.70%PYRGFPyroGenesis Canada+3.33%+17.43%+1.12%-43.91%-69.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGNApexigen 0.00N/AN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/ANNVCNanoViricides 0.00N/AN/AN/APYRGFPyroGenesis Canada 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGNApexigenN/AN/AN/AN/A($0.09) per shareN/AEGRXEagle Pharmaceuticals$257.55M0.08$3.75 per share0.40N/A∞NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/APYRGFPyroGenesis Canada$9.14M3.93N/AN/A($0.01) per share-19.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGNApexigen-$32.07MN/A0.00∞N/AN/A-614.82%-133.30%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/ANNVCNanoViricides-$8.29M-$0.64N/A∞N/AN/A-87.90%-78.69%N/APYRGFPyroGenesis Canada-$21.12M-$0.03N/A∞N/A-115.14%N/A-60.81%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGNApexigenN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/APYRGFPyroGenesis CanadaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGNApexigenN/A0.820.82EGRXEagle PharmaceuticalsN/AN/AN/ANNVCNanoViricidesN/A3.442.47PYRGFPyroGenesis CanadaN/A0.600.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGNApexigen13.65%EGRXEagle Pharmaceuticals85.36%NNVCNanoViricides10.30%PYRGFPyroGenesis Canada0.03%Insider OwnershipCompanyInsider OwnershipAPGNApexigen19.20%EGRXEagle Pharmaceuticals28.90%NNVCNanoViricides4.60%PYRGFPyroGenesis Canada47.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGNApexigen1124.86 million20.09 millionNot OptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataNNVCNanoViricides2017.43 million14.92 millionOptionablePYRGFPyroGenesis Canada90187.53 million96.34 millionNo DataAPGN, PYRGF, NNVC, and EGRX HeadlinesRecent News About These CompaniesHPQ Achieves Pilot-Scale Milestone in Commercial Fumed Silica Production, Sets Sights on Higher-Value Market SegmentSeptember 4, 2025 | markets.businessinsider.comPyroGenesis’ Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4, 2025 | markets.businessinsider.comPyroGenesis' Latest Fumed Silica Test Results Post 3X Increase in Material Surface AreaSeptember 4, 2025 | globenewswire.comPyroGenesis Announces Second Quarter 2025 ResultsAugust 6, 2025 | globenewswire.comPyroGenesis Signs Additional Contract with Constellium to Advance Aluminum Furnace Electrification Using Plasma Torch TechnologyAugust 5, 2025 | globenewswire.comPyroGenesis Schedules Second Quarter 2025 Financial Results and Business Update Conference CallAugust 1, 2025 | globenewswire.comPyroGenesis Receives Initial Contract for Titanium Metal Powder from European Additive Manufacturing CompanyJuly 31, 2025 | globenewswire.comPyroGenesis Confirms Third-Party SEM Analysis Supports Pilot-Scale Fumed Silica Morphology Consistent with Commercial-Grade Fumed SilicaJuly 28, 2025 | globenewswire.comPyroGenesis Announces Completion of Coke-Oven Gas Valorization and Hydrogen Production Project for Tata SteelJuly 15, 2025 | globenewswire.comPyroGenesis Improves Fumed Silica Quality, Purity, and Consistency Across Multiple Production CyclesJuly 8, 2025 | globenewswire.comPyroGenesis Signs $600,000 Contract Targeting Plastic Waste Management Problem in EuropeJuly 2, 2025 | globenewswire.comPyroGenesis Reports Voting Results from 2025 Annual Meeting of Shareholders - MorningstarJune 29, 2025 | morningstar.comMPyroGenesis Reports Voting Results from 2025 Annual Meeting of ShareholdersJune 27, 2025 | globenewswire.comPyroGenesis Confirms Verification of Fumed Silica Samples by Leading Global SupplierJune 12, 2025 | globenewswire.comPyroGenesis Announces Extension to Term of WarrantsJune 9, 2025 | globenewswire.comHigh-Tech Micro Cap Rallies After Securing Boeing Supplier StatusMay 29, 2025 | msn.comPyroGenesis Confirms Receiving Accelerated Customer Request for Fumed Silica SamplesMay 28, 2025 | globenewswire.comPyroGenesis Confirms Production of Fumed Silica at Pilot Scale Following Independent AnalysisMay 21, 2025 | globenewswire.comPyroGenesis Confirms Successful Collection of Material from Fumed Silica Pilot Plant BaghouseMay 15, 2025 | globenewswire.comPyroGenesis, Inc. (PYRGF) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPGN, PYRGF, NNVC, and EGRX Company DescriptionsApexigen NASDAQ:APGNApexigen, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. Apexigen, Inc. was founded in 2010 and is headquartered in San Carlos, California.Eagle Pharmaceuticals NASDAQ:EGRX$1.50 -1.50 (-50.00%) As of 03:09 PM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.NanoViricides NYSE:NNVC$1.42 -0.01 (-0.70%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.PyroGenesis Canada NASDAQ:PYRGF$0.20 +0.01 (+3.01%) As of 03:05 PM EasternPyroGenesis Canada Inc. designs, develops, manufactures, and commercializes plasma processes and solutions worldwide. The company offers DROSRITE, a process for enhancing metal recovery from dross without any hazardous by-products; plasma atomization process that allows produce and sell high purity spherical metal powders; PUREVAP, a process to produce high purity metallurgical and solar grade silicon from quartz; and PUREVAP NSiR, which is designed to transform silicon into spherical silicon nano powders and nanowires for use in lithium-ion batteries. It provides plasma torches and plasma torch systems used toreplace fossil fuel burners in industrial iron ore pelletization process; plasma arc waste destruction systems for waste destruction onboard ships; steam plasma arc refrigerant cracking systems for the destruction of certain refrigerants, including chlorofluorocarbons, hydrofluorocarbons, and hydrochlorofluorocarbons; plasma arc chemical warfare agent destruction systems, which are mobile platforms for the onsite destruction of chemical warfare agents; plasma resource recovery systems for land-based waste destruction and waste-to-energy applications; plasma torches for waste gasification and combustion; and plasma arc gasification and vitrification. In addition, it offers engineering and manufacturing expertise, and contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, additive manufacturing (including 3D printing), oil and gas, and environmental industries. Further, the company provides installation, commissioning, and start-up services. PyroGenesis Canada Inc. is headquartered in Montreal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AI Meets Nuclear: Palantir’s Role in Energy Expansion Adobe Launches Premiere Pro on iPhone, Upside Ahead? Rocket Lab: A Space Giant Hitting New Highs—Time to Chase? After AI Hyperscaler Deal, Is Aehr Test Systems Stock on Sale? Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
